Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Gramicidine C is a **cyclic peptide antibiotic** that consists of ten amino acid residues arranged in a cyclodecapeptide structure. It is naturally produced by *Brevibacillus brevis*, a soil bacterium[2][10]. Gramicidine C forms transmembrane channels in bacterial cell membranes, thereby increasing membrane permeability to monovalent cations. This disrupts normal ionic gradients and leads to cell death[4][6][8]. It is mainly active against **gram-positive bacteria** and is used in topical formulations for treating dermatological or ophthalmic infections. Gramicidine C is part of the gramicidin family, which includes analogues A, B, and D; however, gramicidine C features a key residue mutation (W11Y) that influences its ion transport properties but not its overall backbone conformation[6][8]. Due to systemic toxicity, it is not used internally but formulated in products for local use.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on gramicidine c.